In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2517-2524

  Sleeman, Katrina ^a   Mishin, Vasiliy P ^a   Deyde, Varough M ^a   Furuta, Yousuke ^b   Klimov, Alexander I ^a   Gubareva, Larisa V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR;

ANIMAL CELL; ARTICLE; DRUG INDICATION; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H4N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N2; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS REPLICATION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; PLAQUE ASSAY; PYRAZINES; SWINE; VIRUS REPLICATION;

EID: 77952645453     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01739-09     Document Type: Article

References (61)

1. Abdel-Ghafar, A. N., T. Chotpitayasunondh, Z. Gao, F. G. Hayden, D. H. Nguyen, M. D. de Jong, A. Naghdaliyev, J. S. Peiris, N. Shindo, S. Soeroso, and T. M. Uyeki. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
2. Anonymous. Accessed 25 October 2009. Toyama starts U.S. trials of polymerase inhibitor. FDAnews Drug Pipeline Alert 4. http://www.fdanews.com /newsletter/article?issueId=9890&articleId=91489.
3. Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:433-435.
4. Centers for Disease Control and Prevention. 2008. Influenza activity - United States and worldwide, 2007-08 season. MMWR Morb. Mortal. Wkly. Rep. 57:692-697.
5. Centers for Disease Control and Prevention. Accessed 27 October 2009. Flu activity and surveillance. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/weekly/fluactivity.htm.
6. Centers for Disease Control and Prevention. Accessed 25 October 2009. Interim guidance on antiviral recommendations for patients with novel influenza A(H1N1) virus infection and their close contacts. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/h1n1flu /recommendations.htm. 2009.
7. Centers for Disease Control and Prevention. 2009. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:467-470.
8. Centers for Disease Control and Prevention. Accessed 27 October 2009. Seasonal influenza: the disease. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/about/disease/index.htm.
9. Centers for Disease Control and Prevention. 2009. Swine influenza A (H1N1) infection in two children - Southern California, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 58:400-402.
10. Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant pandemic influenza A (H1N1) virus infection among summer camp attendees in the setting of liberal oseltamivir prophylaxis for influenza-like illness - North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969-972.
11. Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant novel influenza A (H1N1) virus infection in immunosuppressed patients receiving oseltamivir therapy. MMWR Morb. Mortal. Wkly. Rep. 58:893-896.
12. Cheng, P. K., T. W. Leung, E. C. Ho, P. C. Leung, A. Y. Ng, M. Y. Lai, and W. W. Lim. 2009. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg. Infect. Dis. 15:966-968.
13. Cheung, C. L., J. M. Rayner, G. J. Smith, P. Wang, T. S. Naipospos, J. Zhang, K. Y. Yuen, R. G. Webster, J. S. Peiris, Y. Guan, and H. Chen. 2006. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193:1626-1629.
14. Colman, P. M. 2005. Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev. Anti Infect. Ther. 3:191-199.
15. Couzin-Frankel, J. 2009. Swine flu outbreak. What role for antiviral drugs? Science 324:705.
16. Dawood, F. S., S. Jain, L. Finelli, M. W. Shaw, S. Lindstrom, R. J. Garten, L. V. Gubareva, X. Xu, C. B. Bridges, and T. M. Uyeki. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615.
17. De Clercq, E., and J. Neyts. 2007. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol. Sci. 28:280-285.
18. de Jong, M. D., T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, V. C. Bach, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
19. Deyde, V. M., M. Okomo-Adhiambo, T. G. Sheu, T. R. Wallis, A. Fry, N. Dharan, A. I. Klimov, and L. V. Gubareva. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81:16-24.
20. Deyde, V. M., X. Xu, R. A. Bright, M. Shaw, C. B. Smith, Y. Zhang, Y. Shu, L. V. Gubareva, N. J. Cox, and A. I. Klimov. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196:249-257.
21. Dharan, N. J., L. V. Gubareva, J. J. Meyer, M. Okomo-Adhiambo, R. C. McClinton, S. A. Marshall, K. St. George, S. Epperson, L. Brammer, A. I. Klimov, J. S. Bresee, and A. M. Fry. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
22. Diggory, P., C. Fernandez, A. Humphrey, V. Jones, and M. Murphy. 2001. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322:577-579. (Pubitemid 32234531)
23. Freund, B., S. Gravenstein, M. Elliott, and I. Miller. 1999. Zanamivir: a review of clinical safety. Drug Saf. 21:267-281.
24. Furuta, Y., K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, Y. Watanabe, H. Narita, and K. Shiraki. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-981.
25. Furuta, Y., K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
26. Furuta, Y., K. Takahashi, K. Shiraki, K. Sakamoto, D. F. Smee, D. L. Barnard, B. B. Gowen, J. G. Julander, and J. D. Morrey. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82:95-102.
27. Garten, R. J., C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, W. M. Sessions, X. Xu, E. Skepner, V. Deyde, M. Okomo-Adhiambo, L. Gubareva, J. Barnes, C. B. Smith, S. L. Emery, M. J. Hillman, P. Rivailler, J. Smagala, M. de Graaf, D. F. Burke, R. A. Fouchier, C. Pappas, C. M. Alpuche-Aranda, H. Lopez-Gatell, H. Olivera, I. Lopez, C. A. Myers, D. Faix, P. J. Blair, C. Yu, K. M. Keene, P. D. Dotson, Jr., D. Boxrud, A. R. Sambol, S. H. Abid, K. St. George, T. Bannerman, A. L. Moore, D. J. Stringer, P. Blevins, G. J. Demmler-Harrison, M. Ginsberg, P. Kriner, S. Waterman, S. Smole, H. F. Guevara, E. A. Belongia, P. A. Clark, S. T. Beatrice, R. Donis, J. Katz, L. Finelli, C. B. Bridges, M. Shaw, D. B. Jernigan, T. M. Uyeki, D. J. Smith, A. I. Klimov, and N. J. Cox. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
28. Gooskens, J., M. Jonges, E. C. Claas, A. Meijer, P. J. van den Broek, and A. M. Kroes. 2009. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 301: 1042-1046.
29. Govorkova, E. A., N. A. Ilyushina, J. L. McClaren, T. S. Naipospos, B. Douangngeun, and R. G. Webster. 2009. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob. Agents Chemother. 53:3088-3096.
30. Gubareva, L. V., L. Kaiser, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835.
31. Hayden, F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl. 1):S3-S13.
32. Hayden, F. G. 1996. Amantadine and rimantadine-clinical aspects, p. 59-77. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley and Sons Ltd., San Francisco, CA.
33. Hedrick, J. A., A. Barzilai, U. Behre, F. W. Henderson, J. Hammond, L. Reilly, and O. Keene. 2000. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 19:410-417.
34. Hurt, A. C., J. Ernest, Y. M. Deng, P. Iannello, T. G. Besselaar, C. Birch, P. Buchy, M. Chittaganpitch, S. C. Chiu, D. Dwyer, A. Guigon, B. Harrower, I. P. Kei, T. Kok, C. Lin, K. McPhie, A. Mohd, R. Olveda, T. Panayotou, W. Rawlinson, L. Scott, D. Smith, H. D'Souza, N. Komadina, R. Shaw, A. Kelso, and I. G. Barr. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
35. Hurt, A. C., P. Selleck, N. Komadina, R. Shaw, L. Brown, and I. G. Barr. 2007. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73:228-231.
36. Itoh, Y., K. Shinya, M. Kiso, T. Watanabe, Y. Sakoda, M. Hatta, Y. Muramoto, D. Tamura, Y. Sakai-Tagawa, T. Noda, S. Sakabe, M. Imai, Y. Hatta, S. Watanabe, C. Li, S. Yamada, K. Fujii, S. Murakami, H. Imai, S. Kakugawa, M. Ito, R. Takano, K. Iwatsuki-Horimoto, M. Shimojima, T. Horimoto, H. Goto, K. Takahashi, A. Makino, H. Ishigaki, M. Nakayama, M. Okamatsu, K. Takahashi, D. Warshauer, P. A. Shult, R. Saito, H. Suzuki, Y. Furuta, M. Yamashita, K. Mitamura, K. Nakano, M. Nakamura, R. Brockman-Schneider, H. Mitamura, M. Yamazaki, N. Sugaya, M. Suresh, M. Ozawa, G. Neumann, J. Gern, H. Kida, K. Ogasawara, and Y. Kawaoka. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
37. Lackenby, A., O. Hungnes, S. G. Dudman, A. Meijer, W. J. Paget, A. J. Hay, and M. C. Zambon. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. 13:8026.
38. Le, Q. M., M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
39. Matrosovich, M., T. Matrosovich, J. Carr, N. A. Roberts, and H. D. Klenk. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77: 8418-8425. (Pubitemid 36871470)
40. McKimm-Breschkin, J. L., P. W. Selleck, T. B. Usman, and M. A. Johnson. 2007. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13:1354-1357.
41. Medeiros, R., M. A. Rameix-Welti, V. Lorin, P. Ribaud, J. C. Manuguerra, G. Socie, C. Scieux, N. Naffakh, and S. van der Werf. 2007. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir. Ther. 12:571-576.
42. Meijer, A., A. Lackenby, O. Hungnes, B. Lina, S. van der Werf, B. Schweiger, M. Opp, J. Paget, J. van de Kassteele, A. Hay, and M. Zambon. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
43. Mishin, V. P., F. G. Hayden, and L. V. Gubareva. 2005. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49:4515-4520.
44. Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson, P. M. Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25:5086-5096.
45. Monto, A. S. 2003. The role of antivirals in the control of influenza. Vaccine 21:1796-1800.
46. Moscona, A. 2008. Medical management of influenza infection. Annu. Rev. Med. 59:397-413.
47. Moscona, A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
48. Plotkin, S. A. 2005. Vaccines: past, present and future. Nat. Med. 11:S5-S11.
49. Saito, R., T. Sakai, I. Sato, Y. Sano, H. Oshitani, M. Sato, and H. Suzuki. 2003. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J. Clin. Microbiol. 41: 2164-2165.
50. Sheu, T. G., V. M. Deyde, M. Okomo-Adhiambo, R. Garten, X. Xu, R. Bright, E. Butler, T. R. Wallis, A. I. Klimov, and L. V. Gubareva. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2008. Antimicrob. Agents Chemother. 52:3284-3292.
51. Shinde, V., C. B. Bridges, T. M. Uyeki, B. Shu, A. Balish, X. Xu, S. Lindstrom, L. V. Gubareva, V. Deyde, R. J. Garten, M. Harris, S. Gerber, S. Vagasky, F. Smith, N. Pascoe, K. Martin, D. Dufficy, K. Ritger, C. Conover, P. Quinlisk, A. Klimov, J. S. Bresee, and L. Finelli. 2009. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N. Engl. J. Med. 360:2616-2625.
52. Smee, D. F., B. L. Hurst, H. Egawa, K. Takahashi, T. Kadota, and Y. Furuta. 2009. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J. Antimicrob. Chemother. 64:741-746.
53. Smith, B. J., J. L. Kimm-Breshkin, M. McDonald, R. T. Fernley, J. N. Varghese, and P. M. Colman. 2002. Structural studies of the resistance of influenza virus neuraminidase to inhibitors. J. Med. Chem. 45:2207-2212.
54. Smith, G. J., D. Vijaykrishna, J. Bahl, S. J. Lycett, M. Worobey, O. G. Pybus, S. K. Ma, C. L. Cheung, J. Raghwani, S. Bhatt, J. S. Peiris, Y. Guan, and A. Rambaut. 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459:1122-1125.
55. Takahashi, K., Y. Furuta, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, and K. Shiraki. 2003. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14:235-241.
56. Tisdale, M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
57. Weinstock, D. M., and G. Zuccotti. 2009. The evolution of influenza resistance and treatment. JAMA 301:1066-1069.
58. World Health Organization. Accessed 25 October 2009. What is phase 6? World Health Organization, Geneva, Switzerland. http://www.who.int/csr /disease/swineflu/frequently-asked-questions/levels-pandemic-alert/en/index .html.
59. World Health Organization. Accessed 27 October 2009. Update: WHO-confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003-24 November 2006. Wkly. Epidemiol. Rec. 82:41-47. http://www.who .int/wer/2007/wer8206.pdf.
60. World Health Organization. Accessed 27 October 2009. Influenza (seasonal). World Health Organization, Geneva, Switzerland. http://www.who.int /mediacentre/factsheets/fs211/en/.
61. World Health Organization. Accessed 11 August 2009. Pandemic (H1N1) 2009 - update 60. World Health Organization, Geneva, Switzerland. www .who.int/csr/don/2009-08-04/en/print.html.